DE69813194D1 - Assay, verbindungen, therapie und nachweisverfahren um zelluläre dns-reparatur-aktivität zu modulieren - Google Patents

Assay, verbindungen, therapie und nachweisverfahren um zelluläre dns-reparatur-aktivität zu modulieren

Info

Publication number
DE69813194D1
DE69813194D1 DE69813194T DE69813194T DE69813194D1 DE 69813194 D1 DE69813194 D1 DE 69813194D1 DE 69813194 T DE69813194 T DE 69813194T DE 69813194 T DE69813194 T DE 69813194T DE 69813194 D1 DE69813194 D1 DE 69813194D1
Authority
DE
Germany
Prior art keywords
dna repair
dna
cellular dna
assay
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69813194T
Other languages
English (en)
Other versions
DE69813194T2 (de
Inventor
Philip Jackson
Elizabeth Critchlow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kudos Pharmaceuticals Ltd
Original Assignee
Kudos Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9700574.8A external-priority patent/GB9700574D0/en
Priority claimed from GBGB9713131.2A external-priority patent/GB9713131D0/en
Application filed by Kudos Pharmaceuticals Ltd filed Critical Kudos Pharmaceuticals Ltd
Publication of DE69813194D1 publication Critical patent/DE69813194D1/de
Application granted granted Critical
Publication of DE69813194T2 publication Critical patent/DE69813194T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/9015—Ligases (6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69813194T 1997-01-13 1998-01-13 Assay, verbindungen, therapie und nachweisverfahren um zelluläre dns-reparatur-aktivität zu modulieren Expired - Fee Related DE69813194T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9700574 1997-01-13
GBGB9700574.8A GB9700574D0 (en) 1997-01-13 1997-01-13 Methods and means relating to retrotransposon and retroviral integration
GB9713131 1997-06-20
GBGB9713131.2A GB9713131D0 (en) 1997-06-20 1997-06-20 Assays,therapeutic and diagnostic methods and means
PCT/GB1998/000095 WO1998030902A1 (en) 1997-01-13 1998-01-13 Assays, agents, therapy and diagnosis relating to modulation of cellular dna repair activity

Publications (2)

Publication Number Publication Date
DE69813194D1 true DE69813194D1 (de) 2003-05-15
DE69813194T2 DE69813194T2 (de) 2004-02-05

Family

ID=26310785

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69813194T Expired - Fee Related DE69813194T2 (de) 1997-01-13 1998-01-13 Assay, verbindungen, therapie und nachweisverfahren um zelluläre dns-reparatur-aktivität zu modulieren

Country Status (12)

Country Link
US (1) US6753158B1 (de)
EP (1) EP0966683B1 (de)
JP (1) JP2001508868A (de)
AT (1) ATE237136T1 (de)
AU (1) AU724108B2 (de)
CA (1) CA2277481A1 (de)
DE (1) DE69813194T2 (de)
DK (1) DK0966683T3 (de)
ES (1) ES2197453T3 (de)
GB (1) GB2322193B (de)
PT (1) PT966683E (de)
WO (1) WO1998030902A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569681B1 (en) 2000-03-14 2003-05-27 Transkaryotic Therapies, Inc. Methods of improving homologous recombination
DE10161829B4 (de) * 2001-12-15 2006-02-16 Peter Lahnert Neue Methode zur Bestimmung der Telomerlänge und ihre Verwendung zur Abschätzung des Lebensalters
MX349188B (es) 2004-03-15 2017-07-17 Sunesis Pharmaceuticals Inc Sns - 595 y metodos para utilizar el mismo.
US8580814B2 (en) 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
EP2043645A2 (de) 2006-06-12 2009-04-08 Sunesis Pharmaceuticals, Inc. Verbindungen und zusammensetzungen zur behandlung von krebs
WO2012048213A1 (en) * 2010-10-08 2012-04-12 Regents Of The University Of Minnesota A method to increase gene targeting frequency
US20160030404A1 (en) * 2013-03-15 2016-02-04 The Regents Of The University Of California Therapeutic Agents and Methods for the Treatment of DNA Repair Deficiency Disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2132452C (en) 1993-01-21 2003-10-21 The Salk Institute For Biological Studies Casein kinase i-like protein kinase
WO1995010288A1 (en) 1993-10-12 1995-04-20 Baylor College Of Medicine Hepatitis b virus interacts with cellular dna repair processes
WO1996030524A1 (en) 1995-03-31 1996-10-03 Human Genome Sciences, Inc. Human dna ligase iii

Also Published As

Publication number Publication date
CA2277481A1 (en) 1998-07-16
EP0966683A1 (de) 1999-12-29
ATE237136T1 (de) 2003-04-15
JP2001508868A (ja) 2001-07-03
ES2197453T3 (es) 2004-01-01
GB2322193B (en) 1999-09-29
PT966683E (pt) 2003-08-29
WO1998030902A1 (en) 1998-07-16
DK0966683T3 (da) 2003-08-04
US6753158B1 (en) 2004-06-22
GB9800663D0 (en) 1998-03-11
AU724108B2 (en) 2000-09-14
AU5568198A (en) 1998-08-03
EP0966683B1 (de) 2003-04-09
GB2322193A (en) 1998-08-19
DE69813194T2 (de) 2004-02-05

Similar Documents

Publication Publication Date Title
Ruggeri et al. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease
DK1131471T3 (da) Et system til cellebaseret screening
IL147793A0 (en) Optical system analysis of cells
ES2053532T3 (es) Metodos de inmunoensayo.
ATE328891T1 (de) Zusammensetzungen und verfahren zur behandlung und diagnose von immunstörungen
WO2000050872A3 (en) A system for cell-based screening
ZA877719B (en) Immunoassay based on two enzyme inhibition system
AU6104598A (en) Method for isolating, in particular for detecting or quantifying an analyte in amedium
DK153886D0 (da) Fastfasesystem til benyttelse i ligand-receptor analyser
DE69813194D1 (de) Assay, verbindungen, therapie und nachweisverfahren um zelluläre dns-reparatur-aktivität zu modulieren
AR018821A1 (es) Procedimiento para la determinacion de antibioticos con nucleo beta-lactama en un liquido biologico
ATE234467T1 (de) Immunoassay von vollblutproben
Hurwitz et al. Induction of a calcium/calmodulin-dependent phosphodiesterase during phytohemagglutinin-stimulated lymphocyte mitogenesis.
Seagar et al. Photoaffinity labeling of components of the apamin-sensitive K+ channel in neuronal membranes.
KR860006039A (ko) 췌장의 α-아밀라제를 정량하는 방법 및 시약
DE3667858D1 (de) Verfahren und reagenz zur spezifischen bestimmung von pankreas-alpha-amylase.
MX9606065A (es) Proteina fijadora de atp y acidos nucleicos con supuestas propiedades de helicasa y atpasa.
ES2102970B1 (es) Electroinmunoensayos analiticos y electroensayos de reconocimiento biologico.
WO1997020064A3 (de) Verfahren zur beurteilung der aktivität von arzneistoffen
UA28862A (uk) Спосіб визначення необхідності тестування на вілінфекцію

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee